These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 24504937

  • 1. The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT.
    Voors AA, van Veldhuisen DJ, Robertson M, Ford I, Borer JS, Böhm M, Komajda M, Swedberg K, Tavazzi L, SHIFT investigators.
    Eur J Heart Fail; 2014 Apr; 16(4):426-34. PubMed ID: 24504937
    [Abstract] [Full Text] [Related]

  • 2. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M, Swedberg K, Komajda M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L, SHIFT Investigators.
    Lancet; 2010 Sep 11; 376(9744):886-94. PubMed ID: 20801495
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Influence of Cardiovascular and Noncardiovascular Co-morbidities on Outcomes and Treatment Effect of Heart Rate Reduction With Ivabradine in Stable Heart Failure (from the SHIFT Trial).
    Böhm M, Robertson M, Ford I, Borer JS, Komajda M, Kindermann I, Maack C, Lainscak M, Swedberg K, Tavazzi L.
    Am J Cardiol; 2015 Dec 15; 116(12):1890-7. PubMed ID: 26508709
    [Abstract] [Full Text] [Related]

  • 5. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM.
    Am J Cardiovasc Drugs; 2012 Dec 01; 12(6):415-26. PubMed ID: 23181944
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K, Komajda M, Böhm M, Borer J, Robertson M, Tavazzi L, Ford I, SHIFT Investigators.
    J Am Coll Cardiol; 2012 May 29; 59(22):1938-45. PubMed ID: 22617188
    [Abstract] [Full Text] [Related]

  • 8. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z, Rayan M, Saleh A, Abdel-Barr MG, Hussain M, Nammas W.
    Cardiol J; 2015 May 29; 22(2):227-32. PubMed ID: 25179314
    [Abstract] [Full Text] [Related]

  • 9. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY, Huang DJ, Yuan ZY, Zhao RP, Yan XW, Wang MH, Chinese Investigators of SHIFT Study.
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar 24; 45(3):190-197. PubMed ID: 28316174
    [Abstract] [Full Text] [Related]

  • 10. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
    Böhm M, Borer JS, Camm J, Ford I, Lloyd SM, Komajda M, Tavazzi L, Talajic M, Lainscak M, Reil JC, Ukena C, Swedberg K.
    Eur J Heart Fail; 2015 May 24; 17(5):518-26. PubMed ID: 25801408
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Heart rate and its reduction in chronic heart failure and beyond.
    Nikolovska Vukadinović A, Vukadinović D, Borer J, Cowie M, Komajda M, Lainscak M, Swedberg K, Böhm M.
    Eur J Heart Fail; 2017 Oct 24; 19(10):1230-1241. PubMed ID: 28627045
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of ivabradine in patients with chronic systolic heart failure and diabetes: an analysis from the SHIFT trial.
    Komajda M, Tavazzi L, Francq BG, Böhm M, Borer JS, Ford I, Swedberg K, SHIFT Investigators.
    Eur J Heart Fail; 2015 Dec 24; 17(12):1294-301. PubMed ID: 26377342
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
    Cavusoglu Y, Mert U, Nadir A, Mutlu F, Morrad B, Ulus T.
    J Cardiovasc Med (Hagerstown); 2015 Sep 24; 16(9):603-9. PubMed ID: 24922198
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study).
    Borer JS, Böhm M, Ford I, Robertson M, Komajda M, Tavazzi L, Swedberg K, SHIFT Investigators.
    Am J Cardiol; 2014 Feb 01; 113(3):497-503. PubMed ID: 24332674
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study.
    Tavazzi L, Swedberg K, Komajda M, Böhm M, Borer JS, Lainscak M, Ford I, SHIFT Investigators.
    Eur J Heart Fail; 2013 Nov 01; 15(11):1296-303. PubMed ID: 23803951
    [Abstract] [Full Text] [Related]

  • 19. Effect of Visit-to-Visit Variation of Heart Rate and Systolic Blood Pressure on Outcomes in Chronic Systolic Heart Failure: Results From the Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (SHIFT) Trial.
    Böhm M, Robertson M, Borer J, Ford I, Komajda M, Mahfoud F, Ewen S, Swedberg K, Tavazzi L.
    J Am Heart Assoc; 2016 Feb 12; 5(2):. PubMed ID: 26873681
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of ivabradine in heart failure patients with a high-risk profile (analysis from the SHIFT trial).
    Abdin A, Komajda M, Borer JS, Ford I, Tavazzi L, Batailler C, Swedberg K, Rosano GMC, Mahfoud F, Böhm M, SHIFT Investigators.
    ESC Heart Fail; 2023 Oct 12; 10(5):2895-2902. PubMed ID: 37427483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.